South East Cancer Center, University Hospital Waterford, Waterford, Ireland; and Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
J Oncol Pract. 2018 Dec;14(12):701-708. doi: 10.1200/JOP.18.00558.
Biliary tract cancers, including gallbladder cancer, intrahepatic, perihilar, and distal cholangiocarcinomas, although anatomically contiguous, represent a heterogeneous group of cancers with extensive biologic and genetic diversity. With early disease, surgical resection is the preferred option for all subtypes; however, relapse rates remain high, and survival outcomes are poor. Data to guide the use of adjuvant therapy have been limited to retrospective series, population-based studies, and meta-analyses, all with their associated limitations. The number of prospective trials ongoing or completed is increasing, and these results will ultimately dictate optimal treatment of this group of diseases. This review summarizes the data for adjuvant therapy in biliary tract cancers.
胆道癌包括胆囊癌、肝内癌、肝门部癌和远端胆管癌，尽管在解剖上是连续的，但它们是一组具有广泛生物学和遗传多样性的异质性癌症。对于早期疾病，所有亚型首选的治疗方法都是手术切除；然而，复发率仍然很高，生存结果不佳。指导辅助治疗使用的数据仅限于回顾性系列、基于人群的研究和荟萃分析，所有这些都有其相关的局限性。正在进行或已经完成的前瞻性试验的数量正在增加，这些结果最终将决定这组疾病的最佳治疗方法。这篇综述总结了胆道癌辅助治疗的数据。
